Nutrition Research
Volume 30, Issue 1 , Pages 21-26 , January 2010

Optimal cutoff value of high-density lipoprotein cholesterol for predicting coronary artery disease in Taiwanese population

  • Yi-Chia Huang

      Affiliations

    • School of Nutrition, Chung Shan Medical University, Taichung 402, Taiwan
    • ,
  • Chien-Chang Ho

      Affiliations

    • Doctoral Program in Physical Education, Taipei Physical Education College, Taipei 111, Taiwan
    • ,
  • Ping-Ting Lin

      Affiliations

    • School of Nutrition, Chung Shan Medical University, Taichung 402, Taiwan
    • ,
  • Bor-Jen Lee

      Affiliations

    • Intensive Care Unit, Taichung Veterans General Hospital, Taichung 407, Taiwan
    • ,
  • Cheng-Hsiu Lai

      Affiliations

    • Department and Graduate Institute of Physical Education and Health, Taipei Physical Education College, Taipei 111, Taiwan
    • ,
  • Yung-Po Liaw

      Affiliations

    • Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung 402, Taiwan
    • Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung 402, Taiwan. Tel.: +886 4 24730022x11794; fax: +886 4 23248179.

Received 16 September 2009 ,Revised 12 November 2009 ,Accepted 16 November 2009.

References 

  1. Miller M, Mead LA, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol concentrations and angiographically demonstrated coronary artery disease. Am J Cardiol. 1990;65:1–5
  2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and risk of coronary heart diseases. The Framingham study. Ann Intern Med. 1971;74:1–12
  3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8:737–741
  4. National Cholesterol Education Program Adult Treatment Panel III . Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  5. Rudel LL, Kesainiemi A. Low-density lipoprotein particle composition: what is the contribution to atherogenicity?. Curr Opin Lipidol. 2000;11:227–228
  6. Burman A, Jain K, Gulati R, Chopra V, Agarwal DP, Vasisht S. Lipoprotein(a) as a marker of coronary artery disease and its association with dietary fat. J Assoc Physicians India. 2004;52:99–102
  7. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–651
  8. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37–45
  9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714
  10. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–1591
  11. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and atherosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13–27
  12. Barr DP, Russ EM, Eder HA. Protein-lipid relationship in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480–493
  13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III. JAMA. 2001;285:2486–2497
  14. Allison MA, Wright CM. A comparison of HDL and LDL cholesterol for prevalent coronary calcification. Int J Cardiol. 2004;95:55–60
  15. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285–1293
  16. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43–52
  17. Bates CJ, Pentieva KD, Matthews N, Macdonald A. A simple sensitive and reproducible assay for pyridoxal 5′-phosphate and 4-pyridoxic acid in human plasma. Chin Chim Acta. 1999;280:101–111
  18. David WH, Stanley L. In: Applied logistic regression. 2nd ed.. New York: John Wiley & Sons, Inc.; 2000;p. 31–46
  19. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000;15:416–421
  20. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15
  21. Satoh H, Nishino T, Tomita K, Saijo Y, Kishi R, Tsutsui H. Risk factors and the incidence of coronary artery disease in young middle-aged Japanese men: results from a 10-year cohort study. Intern Med. 2006;45:235–239
  22. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA. 1986;256:2823–2828
  23. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidences of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. Am J Cardiol. 1992;70:733–737
  24. Zeljkovic A, Spasojevic-Kalimanovska V, Vekic J, Jelic-Ivanovic Z, Topic A, Bogavac-Stanojevic N, et al. Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?. Clin Exp Med. 2008;8:109–116
  25. Rasouli M, Kiasari AM, Mokhber LV. The ratio of apoB/apoA1, apoB and. lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Med. 2006;44:1015–1021
  26. Sato I, Taniguchi T, Ishikawa Y, Kusuki M, Hayashi F, Mukai M, et al. The lipoprotein fraction between VLDL and LDL detected by biphasic agarose gel electrophoresis reflects serum remnant lipoprotein and Lp(a) concentrations. J Atheroscler Thromb. 2006;13:55–61
  27. Bogavac-Stanojević N, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Spasić S, Kalimanovska-Ostrić D. Lipid and inflammatory markers for the prediction of coronary artery disease: a multi-marker approach. Clin Biochem. 2007;40:1000–1006
  28. Genest J, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792–802
  29. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, Graor RA, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199:223–233

PII: S0271-5317(09)00244-9

doi: 10.1016/j.nutres.2009.11.003

Nutrition Research
Volume 30, Issue 1 , Pages 21-26 , January 2010

Article Tools

* Image Usage & Resolution